Related Experiment Video

Updated: Mar 25, 2026

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K

Chelation therapy in the treatment of cardiovascular diseases

Awais Ibad1, Rabia Khalid1, Paul D Thompson1

  • 1Division of Cardiology, Hartford Hospital, Hartford, CT, USA.

Journal of Clinical Lipidology
|February 20, 2016
PubMed

Insights

Chelation therapy using EDTA may offer benefits for cardiovascular diseases (CVDs), but its effectiveness remains unclear. Further research is needed to confirm its role in reducing recurrent CVD events.

Area of Science:

  • Cardiovascular Science
  • Chelation Therapy Research
  • Medical Treatment Efficacy

Background:

  • Ethylenediaminetetraacetic acid (EDTA) is a chelating agent that binds metals, including calcium.
  • Chelation therapy is proposed to treat cardiovascular disease (CVD) by reducing arterial calcification.
  • The U.S. Food and Drug Administration has not approved chelation therapy, and its efficacy is uncertain.

Purpose of the Study:

  • To examine the effect of chelation therapy on cardiovascular diseases (CVDs).
  • To review existing literature on chelation therapy for CVD treatment.
  • To assess the potential benefits and uncertainties surrounding chelation therapy for CVD.

Main Methods:

  • Systematic literature search of PubMed for English language articles on chelation therapy and CVD events.
  • Detailed review of pertinent articles, including case series and randomized controlled trials.
  • Analysis of findings from identified studies regarding chelation therapy's impact on CVD.

Main Results:

  • 128 articles were identified; 38 were reviewed in detail.
  • Sixteen case series and 3 randomized controlled trials suggested potential benefits of chelation therapy.
  • The Trial to Assess Chelation Therapy (TACT) showed benefit but did not support routine use in post-myocardial infarction patients.

Conclusions:

  • The effectiveness of chelation therapy in reducing recurrent CVD events is currently unclear.
  • There is a possibility that chelation therapy may be beneficial for CVD.
  • Additional, rigorously designed clinical trials are necessary to clarify the role of chelation therapy.
Abstract

Keywords:
Cardiovascular disease preventionCardiovascular disease treatmentCardiovascular diseasesChelation therapyCoronary artery diseaseEDTAIntermittent claudicationPeripheral artery disease

More Related Videos

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol10:12

Enrichment of Mammalian Tissues and Xenopus Oocytes with Cholesterol

Published on: March 25, 2020

6.8K
Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

19.0K

Related Concept Videos

Complexation Equilibria: The Chelate Effect01:19

Complexation Equilibria: The Chelate Effect

In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
1.5K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
398
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
621